Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling

By L. Calvillo, R. Latini, J. Kajstura, A. Leri, P. Anversa, P. Ghezzi, M. Salio, A. Cerami, M. Brines. Proceedings of the National Academy of Sciences of the United States of America, 2003

649 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Oncology

View Paper: https://www.semanticscholar.org/paper/d03dd744e7f32eef48e6ee4ded7389cefdba5832

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. P. Devarajan

Citations in the corpus

• Update on mechanisms of ischemic acute kidney injury. (2006, background): “Similarly, erythropoietin, used extensively in humans for stimulating erythropoiesis, also has prominent antiapoptotic and antiinflammatory actions (179) and has been used successfully for functional amelioration of ischemic AKI in animals (65,77,180).”